New Study Links Cannabis Use to Increased Seizures in Epilepsy Patients

Study Design and Patient Population

Researchers tracked seizure frequency in 847 epilepsy patients over 18 months, comparing cannabis users to matched controls. The cohort included patients with treatment-resistant epilepsy who'd tried at least three FDA-approved anticonvulsants without adequate control. Cannabis users in the study consumed a mix of whole-plant flower, oils, and tinctures—most sourced from state-licensed dispensaries rather than pharmaceutical-grade CBD isolates like Epidiolex.

The variance matters. Epidiolex, the FDA-approved CBD formulation for Dravet syndrome and Lennox-Gastaut syndrome, contains pure cannabidiol with no THC. Most patient-directed cannabis products contain THC ratios ranging from 1:1 to 20:1 CBD:THC. The study didn't control for cannabinoid profiles or dosing consistency.

Seizure Frequency Increased in Cannabis-Using Cohort

Patients using cannabis reported 23% more seizures per month on average than the control group. High-THC products drove the effect most sharply. So did inconsistent cannabinoid ratios. Researchers noted that many patients titrated doses based on subjective feel rather than lab-verified cannabinoid content, introducing significant variability.

The study didn't measure CBD isolate users separately, a critical omission given Epidiolex's proven efficacy in pediatric epilepsy syndromes. That gap leaves open the question of whether whole-plant cannabis specifically—or THC exposure—drives the seizure increase.

Mechanisms Remain Speculative

Study authors propose that THC's psychoactive effects may lower seizure thresholds in susceptible patients, but the mechanism is unproven. THC modulates GABAergic and glutamatergic signaling, both implicated in seizure activity, though the direction of effect varies by dose, frequency, and individual neurology.

One overlooked variable: product contamination. Pesticides, residual solvents, and mold—common in unregulated or poorly tested cannabis—can independently trigger seizures. Participants weren't required to submit products for third-party lab verification, meaning contaminant exposure can't be ruled out as a confounding factor.

Implications for Medical Cannabis Programs

The findings complicate state medical cannabis frameworks that list epilepsy as a qualifying condition without specifying cannabinoid profiles or product types. Most state programs allow patients to access any licensed product, from high-THC concentrates to low-dose CBD tinctures, with minimal clinical oversight. Neurologists have long voiced concern about patients self-medicating with uncharacterized products. This study gives those concerns empirical weight.

For context, see the CannIntel topic hub on cannabis and epilepsy research for the full regulatory and clinical backstory. Epidiolex's 2018 approval created a bifurcated landscape: pharmaceutical CBD with proven efficacy versus dispensary products with variable composition and no clinical trials.

What Epilepsy Patients Should Watch

The study doesn't recommend patients stop cannabis use outright, but it does argue for tighter clinical monitoring and product standardization. Neurologists may begin requesting cannabinoid profiles and third-party lab reports before endorsing cannabis as adjunct therapy. Patients using whole-plant products should track seizure frequency rigorously and consider switching to pharmaceutical-grade CBD if seizures increase.

Next variable to watch: whether state regulators respond by restricting epilepsy patients to low-THC or CBD-dominant products, or whether the medical cannabis industry self-regulates with clearer labeling and dosing guidance. The authors have called for follow-up trials isolating CBD-only users and controlling for product contamination—a signal that this debate isn't settled.